The Public Company Helping Fight Addiction - Lourdes Felix | Seth Farbman's Podcast

In this episode, Seth sits down with Lourdes Felix, CEO & CFO of BioCorRx, to discuss what it really takes to build and lead a publicly traded biotech company focused on substance use disorder. Lourdes shares her journey from finance professional to CEO, her 14+ years with BioCorRx, and how the company has evolved from a reverse merger into a drug-development business working on innovative addiction treatment solutions. They discuss the realities of running a public biotech company, from raising capital and managing investor expectations to navigating clinical trials, regulatory development, and the challenge of being pre-revenue. Lourdes also explains BioCorRx’s approach to medication-assisted treatment and the company’s naltrexone implant technology. The conversation also gets personal, exploring the patients and families who have been impacted by the company’s work and what continues to motivate Lourdes after more than a decade in the industry. Finally, Lourdes discusses BioCorRx’s first revenue-generating commercial asset and what could be next for the company. Subscribe for more conversations with founders, CFOs, and advisors shaping today's capital markets. 00:00 — Introducing Lourdes Felix & BioCorRx 01:42 — Building a Company Around Addiction Treatment 03:52 — How BioCorRx Helps People With Addiction 05:59 — From Finance Professional to CEO 07:43 — Balancing Business With Capital Raising 10:43 — From Finance to the World of Biotech 11:50 — Developing BioCorRx’s Naltrexone Implant 15:18 — The Biggest Misconceptions About Addiction 18:26 — The Patients Who Keep Her Going 19:34 — BioCorRx’s First Revenue-Generating Asset & What’s Next Connect with Seth LinkedIn – https://www.linkedin.com/in/sethfarbman/ Instagram – https://www.instagram.com/sethfarbmanstock TikTok – https://www.tiktok.com/@sethfarbman Twitter (X) – https://x.com/sethfarbman1